Bezafibrate decreases the incidence and delays the onset of type 2 diabetes
Kate Matthews
This article has no abstract so we have provided the first paragraph of the full text.
Type 2 diabetes is a major global health problem that could be prevented by lifestyle changes and pharmacologic therapies that alter primary lipid metabolism. Bezafibrate is a fibrate derivative with triglyceride-lowering and HDL-cholesterol-raising properties that can reduce the incidence of diabetes in patients with impaired fasting glucose levels.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
